Laparoscopic ovarian drilling for ovulation induction in women with anovulatory polycystic ovary syndrome.


Journal

The Cochrane database of systematic reviews
ISSN: 1469-493X
Titre abrégé: Cochrane Database Syst Rev
Pays: England
ID NLM: 100909747

Informations de publication

Date de publication:
11 02 2020
Historique:
entrez: 13 2 2020
pubmed: 13 2 2020
medline: 20 6 2020
Statut: epublish

Résumé

Polycystic ovary syndrome (PCOS) is a common condition affecting 8% to 13% of reproductive-aged women. In the past clomiphene citrate (CC) used to be the first-line treatment in women with PCOS. Ovulation induction with letrozole should be the first-line treatment according to new guidelines, but the use of letrozole is off-label. Consequently, CC is still commonly used. Approximately 20% of women on CC do not ovulate. Women who are CC-resistant can be treated with gonadotrophins or other medical ovulation-induction agents. These medications are not always successful, can be time-consuming and can cause adverse events like multiple pregnancies and cycle cancellation due to an excessive response. Laparoscopic ovarian drilling (LOD) is a surgical alternative to medical treatment. There are risks associated with surgery, such as complications from anaesthesia, infection, and adhesions. To evaluate the effectiveness and safety of LOD with or without medical ovulation induction compared with medical ovulation induction alone for women with anovulatory polycystic PCOS and CC-resistance. We searched the Cochrane Gynaecology and Fertility Group (CGFG) trials register, CENTRAL, MEDLINE, Embase, PsycINFO, CINAHL and two trials registers up to 8 October 2019, together with reference checking and contact with study authors and experts in the field to identify additional studies. We included randomised controlled trials (RCTs) of women with anovulatory PCOS and CC resistance who underwent LOD with or without medical ovulation induction versus medical ovulation induction alone, LOD with assisted reproductive technologies (ART) versus ART, LOD with second-look laparoscopy versus expectant management, or different techniques of LOD. Two review authors independently selected studies, assessed risks of bias, extracted data and evaluated the quality of the evidence using the GRADE method. The primary effectiveness outcome was live birth and the primary safety outcome was multiple pregnancy. Pregnancy, miscarriage, ovarian hyperstimulation syndrome (OHSS), ovulation, costs, and quality of life were secondary outcomes. This updated review includes 38 trials (3326 women). The evidence was very low- to moderate-quality; the main limitations were due to poor reporting of study methods, with downgrading for risks of bias (randomisation and allocation concealment) and lack of blinding. Laparoscopic ovarian drilling with or without medical ovulation induction versus medical ovulation induction alone Pooled results suggest LOD may decrease live birth slightly when compared with medical ovulation induction alone (odds ratio (OR) 0.71, 95% confidence interval (CI) 0.54 to 0.92; 9 studies, 1015 women; I Laparoscopic ovarian drilling with and without medical ovulation induction may decrease the live birth rate in women with anovulatory PCOS and CC resistance compared with medical ovulation induction alone. But the sensitivity analysis restricted to only RCTs at low risk of selection bias suggests there is uncertainty whether there is a difference between the treatments, due to uncertainty around the estimate. Moderate-quality evidence shows that LOD probably reduces the number of multiple pregnancy. Low-quality evidence suggests that there may be little or no difference between the treatments for the likelihood of a clinical pregnancy, and there is uncertainty about the effect of LOD compared with ovulation induction alone on miscarriage. LOD may result in less OHSS. The quality of evidence is insufficient to justify a conclusion on live birth, clinical pregnancy or miscarriage rate for the analysis of unilateral LOD versus bilateral LOD. There were no data available on multiple pregnancy.

Sections du résumé

BACKGROUND
Polycystic ovary syndrome (PCOS) is a common condition affecting 8% to 13% of reproductive-aged women. In the past clomiphene citrate (CC) used to be the first-line treatment in women with PCOS. Ovulation induction with letrozole should be the first-line treatment according to new guidelines, but the use of letrozole is off-label. Consequently, CC is still commonly used. Approximately 20% of women on CC do not ovulate. Women who are CC-resistant can be treated with gonadotrophins or other medical ovulation-induction agents. These medications are not always successful, can be time-consuming and can cause adverse events like multiple pregnancies and cycle cancellation due to an excessive response. Laparoscopic ovarian drilling (LOD) is a surgical alternative to medical treatment. There are risks associated with surgery, such as complications from anaesthesia, infection, and adhesions.
OBJECTIVES
To evaluate the effectiveness and safety of LOD with or without medical ovulation induction compared with medical ovulation induction alone for women with anovulatory polycystic PCOS and CC-resistance.
SEARCH METHODS
We searched the Cochrane Gynaecology and Fertility Group (CGFG) trials register, CENTRAL, MEDLINE, Embase, PsycINFO, CINAHL and two trials registers up to 8 October 2019, together with reference checking and contact with study authors and experts in the field to identify additional studies.
SELECTION CRITERIA
We included randomised controlled trials (RCTs) of women with anovulatory PCOS and CC resistance who underwent LOD with or without medical ovulation induction versus medical ovulation induction alone, LOD with assisted reproductive technologies (ART) versus ART, LOD with second-look laparoscopy versus expectant management, or different techniques of LOD.
DATA COLLECTION AND ANALYSIS
Two review authors independently selected studies, assessed risks of bias, extracted data and evaluated the quality of the evidence using the GRADE method. The primary effectiveness outcome was live birth and the primary safety outcome was multiple pregnancy. Pregnancy, miscarriage, ovarian hyperstimulation syndrome (OHSS), ovulation, costs, and quality of life were secondary outcomes.
MAIN RESULTS
This updated review includes 38 trials (3326 women). The evidence was very low- to moderate-quality; the main limitations were due to poor reporting of study methods, with downgrading for risks of bias (randomisation and allocation concealment) and lack of blinding. Laparoscopic ovarian drilling with or without medical ovulation induction versus medical ovulation induction alone Pooled results suggest LOD may decrease live birth slightly when compared with medical ovulation induction alone (odds ratio (OR) 0.71, 95% confidence interval (CI) 0.54 to 0.92; 9 studies, 1015 women; I
AUTHORS' CONCLUSIONS
Laparoscopic ovarian drilling with and without medical ovulation induction may decrease the live birth rate in women with anovulatory PCOS and CC resistance compared with medical ovulation induction alone. But the sensitivity analysis restricted to only RCTs at low risk of selection bias suggests there is uncertainty whether there is a difference between the treatments, due to uncertainty around the estimate. Moderate-quality evidence shows that LOD probably reduces the number of multiple pregnancy. Low-quality evidence suggests that there may be little or no difference between the treatments for the likelihood of a clinical pregnancy, and there is uncertainty about the effect of LOD compared with ovulation induction alone on miscarriage. LOD may result in less OHSS. The quality of evidence is insufficient to justify a conclusion on live birth, clinical pregnancy or miscarriage rate for the analysis of unilateral LOD versus bilateral LOD. There were no data available on multiple pregnancy.

Identifiants

pubmed: 32048270
doi: 10.1002/14651858.CD001122.pub5
pmc: PMC7013239
doi:

Substances chimiques

Fertility Agents, Female 0

Types de publication

Journal Article Meta-Analysis Research Support, Non-U.S. Gov't Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

CD001122

Commentaires et corrections

Type : UpdateOf

Informations de copyright

Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Références

Fertil Steril. 2005 Sep;84(3):761-5
pubmed: 16169420
Int J Gynaecol Obstet. 2011 Jun;113(3):218-21
pubmed: 21457973
Hum Reprod. 2004 Oct;19(10):2244-50
pubmed: 15242999
Arch Gynecol Obstet. 2010 Nov;282(5):567-71
pubmed: 20577748
Cochrane Database Syst Rev. 2019 Jul 31;7:CD008583
pubmed: 31425630
Hum Reprod. 1994 Jun;9(6):1038-42
pubmed: 7962372
Fertil Steril. 2014 Jan;101(1):270-4
pubmed: 24268702
J Obstet Gynaecol Res. 2006 Jun;32(3):292-8
pubmed: 16764619
Obstet Gynecol. 1992 Jul;80(1):45-7
pubmed: 1534881
J Clin Endocrinol Metab. 1998 Jul;83(7):2361-5
pubmed: 9661609
Int J Gynaecol Obstet. 2010 Feb;108(2):143-7
pubmed: 19892338
Fertil Steril. 2007 Dec;88(6):1678-80
pubmed: 17451693
Int J Gynaecol Obstet. 2010 Mar;108(3):240-3
pubmed: 19944418
Cochrane Database Syst Rev. 2012 Jun 13;(6):CD001122
pubmed: 22696324
J Obstet Gynaecol India. 2017 Oct;67(5):356-362
pubmed: 28867887
Aust N Z J Obstet Gynaecol. 2007 Dec;47(6):508-11
pubmed: 17991119
Surg Endosc. 1990;4(2):103-7
pubmed: 2142827
Hum Reprod. 2004 May;19(5):1110-5
pubmed: 15070878
J Obstet Gynaecol. 2003 May;23(3):289-93
pubmed: 12850864
Zhongguo Zhong Xi Yi Jie He Za Zhi. 2012 Nov;32(11):1492-5
pubmed: 23359971
Clin Obstet Gynaecol. 1985 Sep;12(3):605-32
pubmed: 3933879
J Clin Endocrinol Metab. 2004 Oct;89(10):4801-9
pubmed: 15472166
Gynecol Endocrinol. 2016;32(5):399-402
pubmed: 26670076
J Minim Invasive Gynecol. 2018 Sep - Oct;25(6):1075-1079
pubmed: 29476810
JSLS. 2005 Oct-Dec;9(4):439-41
pubmed: 16381363
Hum Reprod. 2009 Jan;24(1):219-25
pubmed: 18794162
Hum Reprod. 1997 Jul;12(7):1443-7
pubmed: 9262275
Gynecol Endocrinol. 2018 Jul;34(7):616-622
pubmed: 29334275
J Gynecol Obstet Biol Reprod (Paris). 2015 Oct;44(8):692-8
pubmed: 25618178
Fertil Steril. 1981 Sep;36(3):320-5
pubmed: 7286253
Fertil Steril. 1990 Jan;53(1):45-9
pubmed: 2136836
Exp Ther Med. 2015 Oct;10(4):1297-1302
pubmed: 26622481
Reprod Biomed Online. 2010 Mar;20(3):403-9
pubmed: 20089454
J Minim Invasive Gynecol. 2005 Jul-Aug;12(4):355-8
pubmed: 16036198
Fertil Steril. 1993 Nov;60(5):766-70
pubmed: 8224258
Br J Obstet Gynaecol. 1993 Feb;100(2):161-4
pubmed: 8476809
Hum Reprod. 2013 Sep;28(9):2417-24
pubmed: 23820423
Br J Obstet Gynaecol. 1985 Dec;92(12):1258-64
pubmed: 3936533
Fertil Steril. 1991 Dec;56(6):1176-8
pubmed: 1835936
Int J Fertil Steril. 2015 Apr-Jun;9(1):9-16
pubmed: 25918587
Arch Gynecol Obstet. 2009 Oct;280(4):573-8
pubmed: 19214545
Ann Saudi Med. 2000 Mar;20(2):165-7
pubmed: 17322721
Fertil Steril. 1992 Feb;57(2):309-13
pubmed: 1735480
Fertil Steril. 2002 Aug;78(2):404-11
pubmed: 12137881
Arch Gynecol Obstet. 2016 Oct;294(4):791-6
pubmed: 27383413
Cochrane Database Syst Rev. 2007 Jul 18;(3):CD001122
pubmed: 17636653
Hum Reprod. 1996 May;11(5):992-7
pubmed: 8671376
Arch Gynecol Obstet. 2015 May;291(5):1089-94
pubmed: 25304269
Am J Obstet Gynecol. 1987 Feb;156(2):279-85
pubmed: 2950757
Arch Gynecol Obstet. 2010 May;281(5):939-44
pubmed: 19956961
Gynecol Endocrinol. 2017 Jan;33(1):26-29
pubmed: 27228002
Cochrane Database Syst Rev. 2005 Jul 20;(3):CD001122
pubmed: 16034856
J Obstet Gynaecol Res. 2011 Mar;37(3):169-77
pubmed: 21114583
Fertil Steril. 2009 Apr;91(4):1164-7
pubmed: 18342858
Cochrane Database Syst Rev. 2018 May 24;5:CD010287
pubmed: 29797697
Int J Gynaecol Obstet. 2009 Dec;107(3):236-9
pubmed: 19729161
BMJ. 2004 Jan 24;328(7433):192
pubmed: 14739186
Hum Reprod. 2011 Jul;26(7):1899-904
pubmed: 21576081
Hum Reprod. 2012 Dec;27(12):3577-82
pubmed: 23001778
Med J Armed Forces India. 2006 Apr;62(2):119-22
pubmed: 27407876
Fertil Steril. 2010 Jun;94(1):268-75
pubmed: 19409546
Fertil Steril. 1994 Nov;62(5):921-5
pubmed: 7926135
J Pak Med Assoc. 2012 Mar;62(3 Suppl 2):S42-4
pubmed: 22768457
Br J Obstet Gynaecol. 1991 Jan;98(1):30-5
pubmed: 1825605
Hum Reprod. 2004 Aug;19(8):1741-5
pubmed: 15166128
Fertil Steril. 1995 Nov;64(5):930-5
pubmed: 7589636
Fertil Steril. 1975 Sep;26(9):874-6
pubmed: 1183643
Arch Gynecol Obstet. 2013 Feb;287(2):361-7
pubmed: 22941326
Br J Obstet Gynaecol. 1993 Dec;100(12):1082-9
pubmed: 8297840
Fertil Steril. 1984 Jan;41(1):20-5
pubmed: 6692959
Reprod Biomed Online. 2007 Oct;15(4):457-62
pubmed: 17908411
Arch Gynecol Obstet. 2011 Nov;284(5):1303-9
pubmed: 21755338
Eur J Obstet Gynecol Reprod Biol. 2014 Aug;179:163-9
pubmed: 24965999
Clin Endocrinol (Oxf). 1990 Nov;33(5):585-92
pubmed: 2123759
Cochrane Database Syst Rev. 2001;(4):CD001122
pubmed: 11687100
Hum Reprod. 2000 Dec;15(12):2526-30
pubmed: 11098021
Br Med J (Clin Res Ed). 1986 Aug 9;293(6543):355-9
pubmed: 3089520
Am J Obstet Gynecol. 2010 Jun;202(6):577.e1-8
pubmed: 20096821
Reprod Biol Endocrinol. 2019 Feb 6;17(1):17
pubmed: 30728032
J Obstet Gynaecol Res. 2005 Apr;31(2):115-9
pubmed: 15771636
Fertil Steril. 2011 Mar 1;95(3):1115-8
pubmed: 21075366
Arch Gynecol Obstet. 2013 Jul;288(1):119-23
pubmed: 23361456

Auteurs

Esmée M Bordewijk (EM)

Amsterdam UMC, University of Amsterdam, Center for Reproductive Medicine, Amsterdam, Netherlands, 1105 AZ.

Ka Ying Bonnie Ng (KYB)

University of Southampton, School of Human Development and Health, Southampton, UK, SO16 6YD.

Lidija Rakic (L)

Amsterdam UMC, University of Amsterdam, Center for Reproductive Medicine, Amsterdam, Netherlands, 1105 AZ.

Ben Willem J Mol (BWJ)

Monash University, Department of Obstetrics and Gynaecology, 246 Clayton Road, Clayton, Victoria, Australia, 3168.

Julie Brown (J)

Auckland, New Zealand.

Tineke J Crawford (TJ)

The University of Auckland, Liggins Institute, 85 Park Road, Grafton, Auckland, New Zealand, 1023.

Madelon van Wely (M)

Amsterdam UMC, University of Amsterdam, Center for Reproductive Medicine, Amsterdam, Netherlands, 1105 AZ.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH